ARCH Venture Fund XII, L.P. 13D and 13G filings for Neumora Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-22 5:33 pm Purchase | 2024-11-12 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA | ARCH Venture Fund XII, L.P. | 31,979,111 19.800% | 12,904 (+0.04%) | Filing |
| 2023-12-15 5:06 pm Purchase | 2023-12-08 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA | ARCH Venture Fund XII, L.P. | 31,966,207 20.900% | 2,168,831 (+7.28%) | Filing |
| 2023-09-29 8:22 pm Purchase | 2023-09-19 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA | ARCH Venture Fund XII, L.P. | 29,797,376 19.600% | 29,797,376 (New Position) | Filing |